Voronoi Presents 'VRN11' Clinical Results at ESMO… "20% of Brain Metastasis Patients Achieve Complete Remission"
Predicted impact: Medium
Clinical data for a lead drug with strong response; meaningful for a biotech of this size.
Voronoi보로노이
310210 · KOSDAQ · ₩310210 · 보로노이
₩115,200▼ ₩5,900 (4.87%)End-of-day · Oct 29, 2026 · End-of-day prices.
Voronoi Announces Phase 1 Results for Targeted Anticancer Drug 'VRN10'…"Encouraging Results"
Predicted impact: Low
Phase 1 clinical trial results for a drug candidate; no revenue size or financial impact given.
[Exclusive] Voronoi pushes ahead with ₩80B CB issuance… signs of overbooking despite weak share price
Predicted impact: Low
₩80B convertible bond is about 3% of market value; overbooking signals demand, below the ~5% threshold.
Voronoi to raise ₩80B via convertible bonds as strong investor demand brings signs of overbooking
Predicted impact: Medium
₩80B convertible bonds, about 3% of ₩2.47T market value; same issuance already reported, so lowered one level.
[MM] Voronoi pushes ahead with ₩80B convertible bond issue… signs of overbooking despite weak share price
Predicted impact: Medium
₩80B convertible bond is about 3% of market value; overbooking signals demand, below the ~5% threshold.
Vorono rises 7%+ as European trial change approval for lead drug candidate adds countries
Predicted impact: Medium
European trial approval for a lead drug candidate adds countries; meaningful pipeline progress.
Also known as: Voronoi / 보로노이 / 310210 / KRX:310210
Source: KRX statistical information